North America GLP-1 Receptor Agonists Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route of Administration, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
North America · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$23.68 BnPlaceholder estimate
Estimate 2025$27.54 Bn52.5% of the global market
Projected 2034$107.20 Bn 289.2%Adds $79.66 Bn over 9 forecast years
CAGR 2025–203416.3%Faster than 81% of 180 Pharmaceuticals markets here
North America GLP-1 Receptor Agonists Market Analysis at a glance
Market size, 2025
$27.54 Bn placeholder estimate
Forecast, 2034
$107.20 Bn placeholder estimate
Growth (CAGR), 2025–2034
16.3% placeholder estimate
Years
2024 historical · 2025 base year · 2026–2034 forecast
Segments
Drug, route of administration, application and end user (see all)
Key players
Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Amgen Inc. and 1 more (see all)
Active clinical trials
4 in North AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The North America GLP-1 Receptor Agonists Market Analysis Executive Summary
GLP-1 receptor agonists are medicines that mimic a gut hormone to lower blood sugar, slow digestion and reduce appetite. They are used to treat type 2 diabetes and obesity.
Key segments of the GLP-1 Receptor Agonists market include drug (Semaglutide, Tirzepatide and Liraglutide), route of administration (Injectable and Oral) and application (Type 2 Diabetes, Obesity and Cardiovascular Risk Reduction).
North America GLP-1 Receptor Agonists market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
North America GLP-1 Receptor Agonists Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the GLP-1 Receptor Agonists market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the GLP-1 Receptor Agonists market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for GLP-1 Receptor Agonists Market in North America
The GLP-1 Receptor Agonists market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for GLP-1 Receptor Agonists Market in North America
GLP-1 Receptor Agonists in North America: rules, payment and research
In the countries we cover here, medicines are approved by Health Canada (Canada)[1] and FDA (US)[2]. How care is paid for in these countries: provincial health insurance (Canada)[3] and Medicare and Medicaid (US)[4]. ClinicalTrials.gov lists 4 studies on GLP-1 Receptor Agonists that are recruiting, active or about to start in North America.[5]
[5]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for GLP-1 Receptor Agonists. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug
4.2 By Route of Administration
4.3 By Application
4.4 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novo Nordisk
7.2 Eli Lilly and Company
7.3 AstraZeneca
7.4 Sanofi
7.5 Amgen
7.6 Pfizer
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The GLP-1 Receptor Agonists market can be segmented based on various criteria, including drug, route of administration, application and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the GLP-1 Receptor Agonists market in North America?
Placeholder estimate: about $27.54 Bn in 2025, rising to about $107.20 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the GLP-1 Receptor Agonists market in North America growing?
Placeholder estimate: about 16.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the GLP-1 Receptor Agonists market report cover?
The report splits the market by drug (Semaglutide, Tirzepatide, Liraglutide, Dulaglutide and more), route of administration (Injectable, Oral), application (Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the GLP-1 Receptor Agonists market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Amgen Inc. and Pfizer Inc..
What is driving the GLP-1 Receptor Agonists market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market.
How many clinical trials on GLP-1 Receptor Agonists are running in North America?
4 studies are recruiting, active or about to start in North America, counted across the 2 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
How much research is published on GLP-1 Receptor Agonists?
PubMed lists 4,726 papers on GLP-1 Receptor Agonists added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.